NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with InterWest Health to provide the preferred provider organization's members access to GTG's BrevaGen breast cancer diagnostic test.
The deal is the eighth that Melbourne, Australia-based GTG has reached with a US PPO. The deal was forged between its wholly owned subsidiary Phenogen Sciences and InterWest, a regional provider network based in Missoula, Mont. servicing seven states in the northwest US. InterWest's network includes more than 15,000 health care providers, GTG said.